Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Markets Today: Stock Index Futures Climb on Meta’s Earnings

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.47%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.87%. U.S. stock index futures this morning are moderately higher. Strength in technology stocks is lifting the overall market this morning, with Meta Platforms up more...

Barchart

Eli Lilly Unveils New Obesity Data As Mounjaro Blows Past Sales Estimates

Eli Lilly stock surged Thursday after diabetes drug Mounjaro blew past sales projections and led to promising weight loss in a Phase 3 study.

Investors Business Daily

Eli Lilly releases more data for new obesity drug, moving toward fast-track approval

There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

Dow Jones Futures Rise: Meta Soars, Drug Giants Climb, Specialty Chip Plays Dive

Futures: Meta Platforms boomed on earnings, but megacap techs can't hide broad market rally weakness. First Republic dived again.

Investors Business Daily

Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In Obesity

Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment.

Investors Business Daily

Jim Cramer Bluntly Schools Stock-Buyers On 3 'Amazing American' Companies

The CNBC host offers some pointed thoughts.

The Street

Manager Of Top T. Rowe Price Fund Is Still 'Pretty Cautious'

Looking for a go-anywhere stock fund that isn't trapped in a style box and can buy stocks of all sizes and styles? Well, Justin White's T. Rowe Price All-Cap Opportunities Fund checks all those boxes.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Stock Shows Improved Relative Strength; Still Shy Of Benchmark

A Relative Strength Rating upgrade for Eli Lilly shows improving technical performance. Will it continue?

Investors Business Daily

Australian news publishers palm off payment for Twitter Blue verification

Publishers appear unlikely to pay for verification after the platform warned legacy accounts would be stripped of checkmarks from April 1.

Crikey

Novo Hits Another Record High As WHO Considers A Key Move In Obesity

The World Health Organization will consider adding obesity treatments to its "essential medicines list." The move could help some drug stocks.

Investors Business Daily

Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker

Novartis stock surged Monday after the company's treatment reduced the risk of relapse in patients with early-stage breast cancer.

Investors Business Daily

‘I skip meals to make my insulin last’: the cost of diabetes in the global south

The three firms that control the insulin market are to cut costs in the US, but elsewhere users can spend all their pay to get the life-saving drug

The Guardian - UK

Sanofi, joining other drug makers, slashes US insulin price

New York (AFP) - French pharmaceutical giant Sanofi announced on Thursday it would cut the US price of its most prescribed insulin by 78 percent, falling in line with two other major drug makers.

AFP

The biggest U.S. pharmaceutical companies are lowering insulin costs to save themselves money

So much for altruism.

Axios

Get all your
news in one place.

100’s of premium titles.
One news app.

Chicago Sun-Times

Anti-obesity drug demand expected to skyrocket, but will insurance cover the cost?

New weight loss drugs can cost more than $1,000 a month, but most health plans don’t cover them.

Investors Business Daily

Eli Lilly Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark

A Relative Strength Rating upgrade for Eli Lilly shows improving technical performance. Will it continue?

WEKU

Novo Nordisk will cut some U.S. insulin prices by up to 75% starting next year

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

Inverse

This Essential Medical Treatment Could Finally Become Affordable For Everyone

Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70 percent.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed

Eli Lilly stock and Biogen stock diverged Thursday after Lilly said a decade-long study of an Alzheimer's treatment definitively failed.

Miami Herald

$35 for insulin? What to know about Eli Lilly’s price slash for the diabetic medicine

Eli Lilly plans to slash the cost of some of its most popular insulin drugs later this year for people with and without insurance, in a move that could make the lifesaving medication more affordable for some patients living with diabetes.

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily…

Tribune News Service

Editorial: What insulin should cost: Eli Lilly comes through for Americans with diabetes

A hearty thank you to Eli Lilly, one of the planet’s top three producers of insulin, for slashing the price of its most widely prescribed form of insulin by 70% while capping related out-of-pocket costs at $35 a month. That means diabetics with private insurance will now pay costs on…

Tribune News Service

Commentary: Want to make drugs, including insulin, affordable? End patent abuse

Drugmaker Eli Lilly on Wednesday said it will drop prices on some versions of insulin, and cap monthly out-of-pocket costs at $35 per product for insured individuals not covered by Medicare’s prescription drug program, which also maintains a $35 cap. The welcome move comes as lawmakers in both major parties…

The Independent UK

Reporter behind viral Eli Lilly parody account peels back curtain on ‘stupid little tweet’ that helped trigger insulin price cap

Reporter Sean Morrow wants to make sure credit goes to lawmakers working on drug pricing, Graig Graziosi reports

The Conversation

Eli Lilly is cutting insulin prices and capping copays at $35 – 5 questions answered

Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70% and capping insulin copays at US$35 for uninsured patients and those with private health insurance. These changes follow efforts by the federal government, the California state government, nonprofits and some companies…

1 … 17 18 19 20

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations